Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

Antonis Valachis; Laura  Biganzoli; Athina Christopoulou; Kamilla Fjemeros; Elena Fountzila; Jürgen   Geisler; Raquel  Gomez-Bravo; Peeter  Karihtala; Paris Kosmidis; Angelos Koutras; Helena  Linardou; Henrik  Lindman; Iván  Martínez-Ballestero; Anna  Belén Rodríguez; Icro Meattini; Montserrat   Munoz-Mateu; Mukhrizah Othman; Amanda  Psyrri; Emanuela  Risi; Aglaia  Schiza; Nikolaos Spathas; Meri  Utriainen; Luca  Visani; Soledad  Ballesteros; Ioannis  Basdekis; Susanne  Dieroff Hay; Theo Fotis; Samuel Fricker; Gimon  de Graaf; Marit Jenset; Tim Kanters; Kostas   Lampropoulos; Christiana Markou; Kalliopi   Mastoraki; Christina  Nanou; José Manuel  Reales Aviles; Marianne   Santaholma; Thanos  Kosmidis

doi:10.1080/14796694.2024.2413841

Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

Antonis Valachis, Laura Biganzoli, Athina Christopoulou, Kamilla Fjemeros, Elena Fountzila, Jürgen Geisler, Raquel Gomez-Bravo, Peeter Karihtala , Paris Kosmidis, Angelos Koutras, Helena Linardou, Henrik Lindman, Iván Martínez-Ballestero, Anna Belén Rodríguez, Icro Meattini, Montserrat Munoz-Mateu, Mukhrizah Othman, Amanda Psyrri, Emanuela Risi, Aglaia SchizaNikolaos Spathas, Meri Utriainen , Luca Visani, Soledad Ballesteros, Ioannis Basdekis, Susanne Dieroff Hay, Theo Fotis, Samuel Fricker, Gimon de Graaf, Marit Jenset, Tim Kanters, Kostas Lampropoulos, Christiana Markou, Kalliopi Mastoraki, Christina Nanou, José Manuel Reales Aviles, Marianne Santaholma , Thanos Kosmidis

Research output: Contribution to journal › Article › peer-review

Abstract

Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (≥70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment.

Original language	English
Pages (from-to)	1-12
Journal	Future Oncology
DOIs	https://doi.org/10.1080/14796694.2024.2413841
Publication status	Published - 21 Oct 2024

Keywords

advanced breast cancer
CDK4/6 inhibitors
comprehensive geriatric assessment
lower dose
randomized

Access to Document

10.1080/14796694.2024.2413841Licence: CC BY-NC-ND

Implementing geriatric assessment for dose optimization of CDK4 6 inhibitors in older breast cancer patientsFinal published version, 1.59 MBLicence: CC BY-NC-ND

Cite this

Valachis, A., Biganzoli, L., Christopoulou, A., Fjemeros, K., Fountzila, E., Geisler, J., Gomez-Bravo, R., Karihtala , P., Kosmidis, P., Koutras, A., Linardou, H., Lindman, H., Martínez-Ballestero, I., Belén Rodríguez, A., Meattini, I., Munoz-Mateu, M., Othman, M., Psyrri, A., Risi, E., ... Kosmidis, T. (2024). Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients. Future Oncology, 1-12. https://doi.org/10.1080/14796694.2024.2413841

@article{39f967df34a74c9c80bcd48f4f93b7ca,

title = "Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients",

abstract = "Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (≥70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment.",

keywords = "advanced breast cancer, CDK4/6 inhibitors, comprehensive geriatric assessment, lower dose, randomized",

author = "Antonis Valachis and Laura Biganzoli and Athina Christopoulou and Kamilla Fjemeros and Elena Fountzila and J{\"u}rgen Geisler and Raquel Gomez-Bravo and Peeter Karihtala and Paris Kosmidis and Angelos Koutras and Helena Linardou and Henrik Lindman and Iv{\'a}n Mart{\'i}nez-Ballestero and {Bel{\'e}n Rodr{\'i}guez}, Anna and Icro Meattini and Montserrat Munoz-Mateu and Mukhrizah Othman and Amanda Psyrri and Emanuela Risi and Aglaia Schiza and Nikolaos Spathas and Meri Utriainen and Luca Visani and Soledad Ballesteros and Ioannis Basdekis and {Dieroff Hay}, Susanne and Theo Fotis and Samuel Fricker and {de Graaf}, Gimon and Marit Jenset and Tim Kanters and Kostas Lampropoulos and Christiana Markou and Kalliopi Mastoraki and Christina Nanou and {Reales Aviles}, {Jos{\'e} Manuel} and Marianne Santaholma and Thanos Kosmidis",

year = "2024",

month = oct,

day = "21",

doi = "10.1080/14796694.2024.2413841",

language = "English",

pages = "1--12",

}

Valachis, A, Biganzoli, L, Christopoulou, A, Fjemeros, K, Fountzila, E, Geisler, J, Gomez-Bravo, R, Karihtala , P, Kosmidis, P, Koutras, A, Linardou, H, Lindman, H, Martínez-Ballestero, I, Belén Rodríguez, A, Meattini, I, Munoz-Mateu, M, Othman, M, Psyrri, A, Risi, E, Schiza, A, Spathas, N, Utriainen , M, Visani, L, Ballesteros, S, Basdekis, I, Dieroff Hay, S, Fotis, T, Fricker, S, de Graaf, G, Jenset, M, Kanters, T, Lampropoulos, K, Markou, C, Mastoraki, K, Nanou, C, Reales Aviles, JM, Santaholma , M & Kosmidis, T 2024, 'Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients', Future Oncology, pp. 1-12. https://doi.org/10.1080/14796694.2024.2413841

TY - JOUR

T1 - Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

AU - Valachis, Antonis

AU - Biganzoli, Laura

AU - Christopoulou, Athina

AU - Fjemeros, Kamilla

AU - Fountzila, Elena

AU - Geisler, Jürgen

AU - Gomez-Bravo, Raquel

AU - Karihtala , Peeter

AU - Kosmidis, Paris

AU - Koutras, Angelos

AU - Linardou, Helena

AU - Lindman, Henrik

AU - Martínez-Ballestero, Iván

AU - Belén Rodríguez, Anna

AU - Meattini, Icro

AU - Munoz-Mateu, Montserrat

AU - Othman, Mukhrizah

AU - Psyrri, Amanda

AU - Risi, Emanuela

AU - Schiza, Aglaia

AU - Spathas, Nikolaos

AU - Utriainen , Meri

AU - Visani, Luca

AU - Ballesteros, Soledad

AU - Basdekis, Ioannis

AU - Dieroff Hay, Susanne

AU - Fotis, Theo

AU - Fricker, Samuel

AU - de Graaf, Gimon

AU - Jenset, Marit

AU - Kanters, Tim

AU - Lampropoulos, Kostas

AU - Markou, Christiana

AU - Mastoraki, Kalliopi

AU - Nanou, Christina

AU - Reales Aviles, José Manuel

AU - Santaholma , Marianne

AU - Kosmidis, Thanos

PY - 2024/10/21

Y1 - 2024/10/21

N2 - Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (≥70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment.

AB - Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (≥70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment.

KW - advanced breast cancer

KW - CDK4/6 inhibitors

KW - comprehensive geriatric assessment

KW - lower dose

KW - randomized

U2 - 10.1080/14796694.2024.2413841

DO - 10.1080/14796694.2024.2413841

M3 - Article

SN - 1744-8301

SP - 1

EP - 12

JO - Future Oncology

JF - Future Oncology

ER -

Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this